Patent intelligence · US
US 12246059
Stable hybrid FC fusion G-CSF formulation
Stable hybrid FC fusion G-CSF formulation
Patent details — US 12246059
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 11, 2025
- Expiration
- Mar 6, 2045
- Applicant
- ILKOGEN ILAÇ SANAYI VE TICARET A.S.
- Claims
- 10
- CPC classes
- A61K, A61K38/193, A61K47/02, A61K47/10
Quick answer
US 12246059 (Stable hybrid FC fusion G-CSF formulation) is held by ILKOGEN ILAÇ SANAYI VE TICARET A.S.. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ILKOGEN ILAÇ SANAYI VE TICARET A.S.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/193, A61K47/02, A61K47/10, A61K9/0019, A61K9/08
More from ILKOGEN ILAÇ SANAYI VE TICARET A.S.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 12246059?
US 12246059 (Stable hybrid FC fusion G-CSF formulation) is held by ILKOGEN ILAÇ SANAYI VE TICARET A.S.. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12246059?
ILKOGEN ILAÇ SANAYI VE TICARET A.S. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 12246059 expire?
Our index shows an expiration date of Mar 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.